Steven Lichtman
Stock Analyst at Oppenheimer
(3.10)
# 1,320
Out of 4,944 analysts
68
Total ratings
43.75%
Success rate
13.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Lichtman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DXCM DexCom | Maintains: Outperform | $95 → $102 | $79.96 | +27.56% | 9 | Jul 31, 2025 | |
| BSX Boston Scientific | Maintains: Perform | $110 → $118 | $102.50 | +15.12% | 3 | Jul 24, 2025 | |
| PODD Insulet | Maintains: Outperform | $312 → $324 | $308.68 | +4.96% | 6 | May 9, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $145 → $135 | $103.22 | +30.79% | 7 | Oct 15, 2024 | |
| MNKD MannKind | Maintains: Outperform | $10 → $12 | $3.73 | +221.72% | 2 | Aug 28, 2024 | |
| ALC Alcon | Maintains: Outperform | $103 → $110 | $86.48 | +27.20% | 3 | Aug 22, 2024 | |
| MDT Medtronic | Maintains: Perform | $92 → $94 | $92.91 | +1.17% | 10 | Aug 21, 2024 | |
| RXST RxSight | Maintains: Outperform | $72 → $65 | $8.31 | +682.19% | 8 | Aug 6, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Outperform | $47 → $58 | $11.13 | +421.11% | 1 | Jun 10, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $10 → $11 | $12.70 | -13.39% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $9.06 | +32.45% | 2 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $82 → $87 | $86.15 | +0.99% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $3.5 | $0.73 | +378.60% | 2 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $273 → $288 | $378.95 | -24.00% | 2 | Jul 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $105 | $91.79 | +14.39% | 3 | Jul 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | $150 | $28.21 | +431.73% | 1 | Jul 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $83 → $85 | $74.27 | +14.45% | 3 | Sep 4, 2020 |
DexCom
Jul 31, 2025
Maintains: Outperform
Price Target: $95 → $102
Current: $79.96
Upside: +27.56%
Boston Scientific
Jul 24, 2025
Maintains: Perform
Price Target: $110 → $118
Current: $102.50
Upside: +15.12%
Insulet
May 9, 2025
Maintains: Outperform
Price Target: $312 → $324
Current: $308.68
Upside: +4.96%
Zimmer Biomet Holdings
Oct 15, 2024
Maintains: Outperform
Price Target: $145 → $135
Current: $103.22
Upside: +30.79%
MannKind
Aug 28, 2024
Maintains: Outperform
Price Target: $10 → $12
Current: $3.73
Upside: +221.72%
Alcon
Aug 22, 2024
Maintains: Outperform
Price Target: $103 → $110
Current: $86.48
Upside: +27.20%
Medtronic
Aug 21, 2024
Maintains: Perform
Price Target: $92 → $94
Current: $92.91
Upside: +1.17%
RxSight
Aug 6, 2024
Maintains: Outperform
Price Target: $72 → $65
Current: $8.31
Upside: +682.19%
Tandem Diabetes Care
Jun 10, 2024
Maintains: Outperform
Price Target: $47 → $58
Current: $11.13
Upside: +421.11%
BrainsWay
May 9, 2024
Maintains: Outperform
Price Target: $10 → $11
Current: $12.70
Upside: -13.39%
Apr 5, 2024
Upgrades: Outperform
Price Target: $12
Current: $9.06
Upside: +32.45%
Feb 29, 2024
Maintains: Outperform
Price Target: $82 → $87
Current: $86.15
Upside: +0.99%
Sep 19, 2023
Reiterates: Outperform
Price Target: $3.5
Current: $0.73
Upside: +378.60%
Jul 28, 2021
Maintains: Perform
Price Target: $273 → $288
Current: $378.95
Upside: -24.00%
Jul 14, 2021
Downgrades: Perform
Price Target: $105
Current: $91.79
Upside: +14.39%
Jul 9, 2021
Initiates: Perform
Price Target: $150
Current: $28.21
Upside: +431.73%
Sep 4, 2020
Maintains: Perform
Price Target: $83 → $85
Current: $74.27
Upside: +14.45%